162P Efficacy and safety of GEMOX (gemcitabine plus oxaliplatin) plus sintilimab and bevacizumab as a conversion therapy in patients with initially unresectable biliary tract cancers (BTC): A single-arm, phase II study. (December 2022) - Zhang, N.